Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Initiates a Combined Phase I\/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"NMD PHARMA"},{"company":"NMD PHARMA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I\/IIa Clinical Trial of NMD670","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"NMD PHARMA"},{"company":"NMD PHARMA","sponsor":"Jeito Capital","pharmaFlowCategory":"D","amount":"$39.6 million","upfrontCash":"Undisclosed","newsHeadline":"NMD Pharma Raises \u20ac35 Million in a New Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"NMD PHARMA"}]

NMD PHARMA

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

NMD Pharma Raises €35 Million in a New Financing

Details:

Proceeds from the financing will be used to support the company as it progresses its lead candidate, NMD670, through completion of the ongoing Phase 2a proof-of-concept trial in patients with Myasthenia Gravis (MG).

Lead Product(s): NMD670

Therapeutic Area: Immunology Product Name: NMD670

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Jeito Capital

Deal Size: $39.6 million Upfront Cash: Undisclosed

Deal Type: Financing February 15, 2022

ASK
US

Upload
your Pipeline Activity

NMD PHARMA

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670

Details:

NMD670 is in development to treat the symptoms of MG and is also being evaluated for the treatment of other neuromuscular diseases.

Lead Product(s): NMD670

Therapeutic Area: Immunology Product Name: NMD670

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2021

ASK
US

Upload
your Pipeline Activity

NMD PHARMA

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis

Details:

NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel.

Lead Product(s): NMD670

Therapeutic Area: Immunology Product Name: NMD670

Highest Development Status: Phase I/ Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 06, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY